Managing Immune-Related Adverse Events
An overview of the potential immune-related adverse events that can arise from treatment with checkpoint inhibitors.
All articles by Andrea S. Blevins Primeau, PhD, MBA
Ivermectin Induces Apoptosis Through Mitochondrial Dysfunction in CML Cells
A recent study sought to determine the effect of ivermectin against CML cells, whether ivermectin can sensitize cells to BCR-ABL TKIs, and its mechanism of action.
Molecular Response and Sokal Score Associated with Treatment-free Remission Duration in CML
A subset of patients with chronic-phase CML in the ENESTfreedom study maintained treatment-free remission for at least 96 weeks after being treatment with frontline nilotinib.
Patients with Chronic Myeloid Leukemia at Increased Risk of Secondary Cancers
Recently published findings suggest that patients with CML, particularly men, have a 30% higher risk of developing secondary cancers; however the cause of this increased risk is unclear.
R-CHOP, R-CVP Confer Favorable Outcomes in Follicular Lymphoma
The open-label, multicenter, phase 3 FOLL05 trial included untreated patients with grade 1, 2, or 3a and Ann Arbor stage II to IV disease. This analysis included 504 evaluable patients.
Midostaurin Plus Chemotherapy Prolongs Survival in AML With FTL3 Mutation
Adding midostaurin — a multi-targeted kinase inhibitor — to chemotherapy prolongs overall survival (OS) among patients with newly diagnosed AML and an FLT3 mutation.
Phase 3 Vadastuximab Talirine Trials Halted Due to Deaths
The data showed a higher rate of death, including fatal infections, in the vadastuximab talirine arm compared with the chemotherapy-only arm.
FDA Expands Daratumumab Approval for Multiple Myeloma
The FDA approved daratumumab in combination with pomalidomide and dexamethasone for the third-line treatment of patients with multiple myeloma.
Response-based Therapy Intensification Improves Survival in Adult ALL
Early response-based treatment intensification with allo-SCT improved OS among adult patients with early thymic precursor T cell ALL.
Prolonged PFS With Brentuximab Vedotin in Cutaneous T Cell Lymphoma
Brentuximab vedotin significantly prolonged PFS with higher response rates compared with methotrexate or bexarotene among patients with CTCL.
Next post in Lymphoma
